June 15, 2024 – Everest Pharma has announced the launch of Resiliva, the world’s first generic version of Resmetirom, marking a significant milestone in the treatment of metabolic and liver diseases. Resiliva is expected to provide an affordable and accessible alternative to the branded medication, particularly for patients suffering from non-alcoholic steatohepatitis (NASH) with liver fibrosis.
Resmetirom, a selective thyroid hormone receptor-beta (THR-β) agonist, has been a groundbreaking drug in addressing NASH, a progressive liver disease with limited treatment options. By introducing Resiliva, Everest Pharma aims to expand global access to this innovative therapy, especially in emerging markets where affordability remains a key concern.
“We are proud to introduce Resiliva as the first generic alternative to Rezdiffra,” said Mr. Anwarul Hoq, CEO of Everest Pharma. “This launch reinforces our commitment to providing high-quality, cost-effective treatments for chronic liver diseases and addressing the unmet needs of millions worldwide.”
The introduction of Resiliva is expected to enhance competition in the pharmaceutical market, potentially reducing the overall cost of NASH treatments. Everest Pharma has assured that the generic maintains the same efficacy, safety, and quality standards as the branded version, ensuring its credibility among healthcare professionals.
As the first pharmaceutical company to successfully introduce a Resmetirom generic, Everest Pharma has positioned itself at the forefront of innovative and accessible liver disease treatments. The medical community and patients alike await the impact of Resiliva on the future of NASH care and metabolic health.
About Everest Pharma: Everest Pharma is a leading pharmaceutical company dedicated to bringing high-quality, affordable medications to patients worldwide. With a strong focus on innovation and accessibility, the company continues to develop and distribute essential therapies across multiple therapeutic areas.
For more information on Resiliva and Everest Pharma’s portfolio, visit https://resilivabd.com/ or https://www.everestpharmabd.com/
